STATERA THERAPEUTICS INC.

Biotech · Private

Spatiotemporally Tuned Particle (STP) nanocarrier platform delivering rapamycin and myelin autoantigens to antigen-presenting cells for immune tolerance induction in multiple sclerosis

Grants
$295K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Spatiotemporal tuning of myelin antigens and rapamycin for enhanced antigen-specific immune tolerance in multiple sclerosis.$295,051
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3027Montai Therapeutics——
3028Parabricks Inc.——
3029LATTICE THERAPEUTICS INC——
3030STATERA THERAPEUTICS INC.——
3031Expedition Medicines——
3032HUMURINE TECHNOLOGIES, INC.——
3033PHENVOGEN, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.